Close Menu

ORLANDO – Older AML patients are not typically offered germline genetic testing to assess their inherited risk for myeloid malignancies. However, such testing may provide an opportunity to manage cancer risk in families, as well as evaluate relatives' suitability for donating stem cells, the results of a study presented at the American Society of Hematology annual meeting suggest. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.